First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease ...

The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...

Live Science spoke with the scientists behind an upcoming clinical trial testing an immune therapy for depression.

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and ...

Keenova Therapeutics plc announced the first-time publication of a retrospective analysis using previously generated XIAFLEX® (collagenase clostridium histolyticum) data. The analysis evaluates ...

Melissa Claire Egan, known for her roles in daytime soap operas "The Young and the Restless" and "All My Children," revealed she was diagnosed with coronary heart disease in late January. The actress, ...

The Food and Drug Administration (FDA) announced a new proposal Monday for flexible drug approval pathway treatments addressing ultrarare diseases. The FDA unveiled draft guidance on a proposed ...

Shares of Japan's Sumitomo Pharma fell over 15%. Japanese government endorsed the company's iPS cell-based therapy for Parkinson's and heart disease. Shares of Japanese drugmaker Sumitomo Pharma fell ...

A potential weapon against Alzheimer’s disease could be hidden in aloe vera, scientists recently uncovered. Aloe vera, a rubbery green plant, may be best known for its skin-soothing qualities, but a ...

A genetics‑guided small molecule called compound 6 gently turns down an overactive immune pathway (CARD9), offering a more precise, durable, and potentially safer treatment strategy for Crohn’s ...

Feb 5 (Reuters) - (This Feb 5 story has been corrected to fix Prolia's 2025 sales to $4.4 billion, not $1.05 billion, in paragraph 5) Sign up here. Its pharmacy benefit management unit, Caremark, will ...

Susannah Rosen was diagnosed with a KIF1A gene mutation at the age of 2½. Patients diagnosed with severe KIF1A gene mutations may live only into early childhood, while patients with mild symptoms can ...